Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced that the US Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine) Extended-Release tablets as once-a-day add-on therapy for epilepsy patients with partial onset seizures.
Subscribe to our email newsletter
Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization.
Lamictal XR reduced the frequency of partial seizures during a 19-week study. More patients who took Lamictal XR had a significant reduction in seizure frequency, as compared to placebo.
Dean Naritoku, Professor and Chairman of neurology, said: Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines even more challenging.”
“Lamictal XR is an important once-daily advance for patients with epilepsy who still experience seizures while taking their current therapy, he added.